New Drug Application (NDA)

New Drug Application (NDA) is a regulatory submission to obtain approval for marketing a drug based on safety and efficacy data.

New Drug Application New Drug Application (NDA)

• An NDA is a comprehensive submission to the FDA requesting approval to market a new pharmaceutical for sale in the U.S.
• The NDA must provide sufficient evidence of the drug’s safety, efficacy, and quality.

Key Sections of an NDA

1. Administrative Information

   • Forms and Cover Letters: Including Form FDA 356h.

2. Summary Documents

   • Overall Summary: High-level overview.
   • Clinical Overview: Summary of clinical data.
   • Non-Clinical Overview: Summary of non-clinical data.

3. Quality (CMC) Module

   • Detailed information on drug substance and product manufacturing.

4. Non-Clinical Study Reports

   • Pharmacology and Toxicology Studies: Full reports.

5. Clinical Study Reports

   • Efficacy Studies: Phase II and III trials.
   • Safety Data: Adverse events, laboratory findings.

6. Statistical Data

   • Statistical Analysis Plans: Methodologies used.
   • Data Listings and Tabulations

7. Labeling

   • Proposed package insert, prescribing information.

8. Patent Information

   • Details of patent exclusivity.

9. Other Information

   • Environmental Assessment
   • Risk Management Plans

FDA Review Process

• Filing Review: FDA determines if the NDA is complete.
• Review Team Assignment: Multidisciplinary team evaluates the NDA.
• Review Clock: Standard review (10 months) or priority review (6 months).
• Advisory Committee Meetings: External experts may be consulted.
• FDA Decision: Approval, Complete Response Letter (requiring additional information), or denial.

Click Here to Watch the Best Pharma Videos